CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 148 enrolled
Drug / intervention
carboxymethylcellulose sodium based new eye drop formulation +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01886690
NCT01886690Phase 3Completed

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Allergan·interventional·Posted Jun 26, 2013·Updated Apr 16, 2019

In Brief

A Phase 3 clinical trial evaluating carboxymethylcellulose sodium based new eye drop formulation and carboxymethylcellulose sodium based eye drops for Bilateral LASIK Surgery. Completed, enrolled 148 participants across 2 sites in 2 countries.

Detailed Summary

This study will compare the safety and efficacy of a new eye drop formulation with REFRESH PLUS® in participants following LASIK surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 26, 2013
Enrollment StartAug 20, 2013
Primary CompletionAug 18, 2014
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 13.0 years ago

Interventions

carboxymethylcellulose sodium based new eye drop formulationdrug

1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.

carboxymethylcellulose sodium based eye dropsdrug

1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.